Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 1783  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Articlesmenu-bullet Search Instructions Online Submission Subscribe Etcetera Contact
 :: Next article
 :: Previous article 
 :: Table of Contents
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::Related articles
 ::  Article in PDF (1,414 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  Abstract
 ::  Positron Emissio...
 ::  FDG PET in Head-...
 ::  FDG PET in Lung ...
 ::  FDG PET in Lymphoma
 ::  FDG PET in Malig...
 ::  FDG PET in Breas...
 ::  FDG PET in Color...
 ::  Somatostatin Rec...
 ::  Detection of Bon...
 ::  Conclusion
 ::  References
 ::  Article Figures

 Article Access Statistics
    PDF Downloaded144    
    Comments [Add]    
    Cited by others 2    

Recommend this journal


Year : 2010  |  Volume : 56  |  Issue : 2  |  Page : 103-108

PET-CT in oncology

Bio-Imaging Unit, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai-400 012, Maharashtra, India

Date of Submission08-Mar-2009
Date of Decision19-Jan-2010
Date of Acceptance18-Feb-2010
Date of Web Publication8-Jul-2010

Correspondence Address:
N C Purandare
Bio-Imaging Unit, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai-400 012, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0022-3859.65277

Rights and Permissions

 :: Abstract 

Diagnostic imaging plays a pivotal role in cancer management. Imaging has made rapid strides in the past few years with new modalities and new indications getting added all the time. Molecular and metabolic imaging with 18F Flurodeoxyglucose Positron Emission Tomography (FDG PET) and other non-FDG isotopes have revolutionized oncologic imaging and changed our approach towards cancer diagnosis, staging and imaging surveillance. The evidence for the use of FDG PET is mounting every day with newer indications getting added to the literature. The main focus of our discussion will be to understand the basic principles of FDG PET imaging and to study a few of its clinical applications in oncology.

Keywords: Diagnostic imaging, humans, neoplasms, positron emission tomography

How to cite this article:
Purandare N C, Rangarajan V. PET-CT in oncology. J Postgrad Med 2010;56:103-8

How to cite this URL:
Purandare N C, Rangarajan V. PET-CT in oncology. J Postgrad Med [serial online] 2010 [cited 2023 Jun 5];56:103-8. Available from:

In the past few decades, as oncologists and oncosurgeons attempted to cure many types of cancers or at least provide patients with a longer disease-free life, there has been a spectacular parallel and supportive evolution in imaging technology. Currently, imaging plays a pivotal role in the management of all cancers. It is used for screening, for preliminary diagnosis, to establish the extent and distribution of disease, for biopsy guidance, staging, prognostication, therapeutic planning, judging response to therapy and restaging. In oncology, the role of imaging has shifted from merely providing anatomical information to providing insight into tumor biology using techniques such as Computerised Tomography (CT) and Magnetic Resonance Imaging (MRI) perfusion imaging, MR spectroscopy and Positron Emission Tomography (PET) imaging. These techniques can demonstrate metabolic response to therapy which precedes anatomical changes. If there is less than optimal response to treatment on early assessment then the treatment regime can be changed accordingly, thus avoiding the potential morbidities associated with a toxic treatment regime which has no therapeutic benefit.

 :: Positron Emission Tomography Top

18 F-Flurodeoxyglucose (FDG) PET has in the last few years become an established modality in the management of several cancers. It is an imaging technique that provides information about the functional and metabolic changes associated with cancer. PET scanning requires the use of molecules that are labeled with radio nuclides. Numerous such positron-emitting radio-isotopes exist and are used in clinical experiments and research. However, in clinical practice the principal radio-isotope used is the positron-emitting 18 F-FDG which is a glucose analogue labeled with 18 F. The positron emitters including 18 F FDG have short half lives and are produced in cyclotrons. FDG is injected intravenously and is transported from the plasma to the cells by glucose transporters (GLUT 1 and GLUT 4). It then undergoes phosphorylation within the cell by the enzyme hexokinase and is converted to FDG-6-phosphate. FDG-6-phosphate is not further metabolized and gets trapped in the cell. Cancer cells demonstrate increased anaerobic glycolysis (Warburg effect) [1] which is believed to be due to upregulation of glucose transporters and hexokinase and reduced levels of glucose-6-phosphatase thus limiting further metabolism of the tracer in cancer cells. [2] The basic aspects of FDG PET and PET-CT such as radiopharmaceuticals, instrumentation, scanning protocol, physiological uptake patterns and benign variants are beyond the scope of this article. The current clinical indications and future applications of FDG PET in certain common cancers will be subsequently discussed.

FDG PET and PET-CT play an important role in the initial diagnosis, staging, response assessment and restaging of various cancers. The common cancers which can be evaluated by PET that are approved by the Centers for Medicare and Medicaid services (CMS) United States, include melanoma, lymphoma, lung cancer, esophageal cancer, head and neck cancer, breast cancer and thyroid cancer. PET, however, has been found to be useful in several other cancers such as gastric cancer, testicular cancer, endometrial and ovarian cancers, hepatocellular carcinoma, biliary and pancreatic cancers and soft tissue sarcomas. A national PET registry has been established in the United States to increase coverage of FDG PET studies for cancers which are not covered by medicare. No such registry or guidelines exist in India, the indications for PET scanning being largely based on Western data and literature.

 :: FDG PET in Head-Neck and Thyroid Cancer Top

For head and neck squamous cell cancers (HNSCC), PET can be used for initial staging, monitoring response to therapy, restaging and long-term surveillance. PET and PET-CT have a limited role in defining the T stage of the primary. MRI and contrast-enhanced CT scan due to their better resolution and ability to depict anatomy in detail are preferred over PET scan. However, PET-CT performed with intravenous contrast is a good alternative for assessing the primary tumor extent at initial presentation. [3] It plays an important role in identifying disease in nodes in unexpected locations and also in detecting unexpected distant metastatic sites. In patients with advanced loco-regional disease PET can detect occult distant metastatic disease in up to 10% of patients. [4] The inherent whole body coverage of PET as compared to the more loco-regional approach of CT and MRI scanning makes it more suitable to unmask sites of unexpected distant metastases. In the setting of clinically N0 (nodes not palpable at initial presentation) PET has not been found to be very useful as per recent literature. [5] This is because of the limited resolution of PET for lesions less than 5 mm and its inability to detect microscopic disease. Selective neck dissection and sentinel node biopsy is more useful in this regard. In patients presenting with cervical nodal metastases detection of primary tumor site is important as it may define the site and extent of surgery and also delineate the field of radiotherapy. Multiple studies have evaluated the role of PET in detecting occult primary with variable results. The sensitivity of PET to detect the primary site of tumor varies from 10-60% according to recent review of 11 studies. [6] PET-CT has been found to be very useful in the setting of assessment after chemoradiation. It has a higher specificity for detecting residual disease than contrast CT when it is performed eight weeks after treatment. [7] Numerous studies have shown that PET has a very good accuracy in detecting local and regional nodal recurrences during surveillance. It is of particular value in detecting sites of distant failure before a definitive salvage therapy is planned for loco-regional recurrence. For well-differentiated thyroid cancers PET-CT is used to detect sites of metastatic disease which are scintigraphically negative on radioiodine studies with persistently high thyroglobulin levels. [8] Similarly, for patients of medullary cancers with high calcitonin levels, PET-CT has been found to be useful to detect sites of disease recurrence. [9]

 :: FDG PET in Lung Cancer Top

FDG PET is an integral part of staging of non-small cell lung cancer (NSCLC) as it very often improves the detection of nodal and distant metastases thus altering patient management. Though PET has a very good sensitivity in detecting the primary tumor it is not very often used for initial T staging owing to the better resolution of contrast-enhanced CT scan which can provide the anatomic detail that is required for surgical planning. Since surgical resection and future use of adjuvant therapy depends on the nodal stage, increasing emphasis is being laid on the ability of PET to accurately stage mediastinal nodal disease. FDG PET complements CT findings in providing information about loco-regional nodal disease that can impact patient management. In a recent meta-analysis comparing PET and CT in mediastinal nodal staging of NSCLC patients, PET showed an overall sensitivity of 83% and specificity of 92% compared with overall sensitivity of 52% and specificity of 78% for CT scan. [10] Owing to the high negative predictive value of a normal PET for excluding mediastinal nodal disease there have been reports suggesting the need to obviate mediastinoscopy if a PET scan is negative for mediastinal nodes. However, there is still no definite consensus on this issue and invasive staging of the mediastinum is still recommended by many authors despite a negative PET scan.

For metastatic disease whole body PET imaging is being increasingly used due to its better accuracy. It has a higher sensitivity, specificity than CT for detecting disease in bones, adrenals and extrathoracic lymph nodes. PET imaging stages intra and extrathoracic disease in a single study, detects occult metastasis in up to 24% cases selected for curative surgical resection and is also found to be cost-effective. [11],[12] FDG PET is also being evaluated for assessing the prognosis and therapeutic response. Studies have shown that when PET is performed after completion of chemoradiation there is a strong association between decrease in FDG uptake of the primary tumor and nodes and the patient outcome [13] and also that PET is superior to CT in response assessment [Figure 1]. There is also evidence that PET performed as early as after one cycle of chemotherapy can predict responders early who have better long-term survival as compared to the PET non-responders. [14] PET has been very useful in detecting tumor recurrence after definitive surgery, chemo or radiation therapy earlier than conventional imaging modalities. For the evaluation of a solitary pulmonary nodule (SPN) PET is used to differentiate between benign and malignant nodules. Generally speaking an SPN with intense FDG uptake is considered to be malignant and a standardized uptake value (SUV) of 2.5 is considered to be a cutoff above which lesions are more likely to be malignant. However, this is not always true and infective/granulomatous lesions like tuberculosis, sarcoidosis etc can show intense FDG uptake whereas cancers like bronchioloalveolar carcinomas (BAC) may show poor or no FDG uptake.

 :: FDG PET in Lymphoma Top

Lymphoma is probably the most frequent indication in oncology for performing PET scans. Whole body FDG PET plays a vital role in almost all the aspects of the workup of lymphoma like initial diagnosis, staging, restaging, assessing response to therapy and long-term surveillance. Not all lymphomas are equally FDG avid. It is important to be aware of the histology before interpreting the results of the PET study. Hodgkin's disease (HD), diffuse large B cell lymphoma (DLBCL), follicular lymphoma and mantle cell lymphoma show good degree of FDG avidity. Peripheral T cell lymphoma and marginal zone lymphoma show poor to moderate FDG uptake. PET is considered to be as good or superior to CT scanning in the staging of lymphomas. It is definitely better in detection of extra-nodal disease and in particular splenic involvement. [15] It plays a complementary role to bone biopsy to assess bone marrow involvement. [16] FDG PET-CT has found to more accurate and better than CT alone and PET alone for staging and is also cost-effective. The degree of FDG uptake correlates well with the histological grade of lymphoma and provides important information about the prognosis. [17]

A negative FDG PET scan at the end of therapy indicates excellent treatment response, good prognosis and a possible progression-free survival [Figure 2], whereas persistent increased FDG uptake during or at the end of therapy is indicative of residual disease and a high chance of relapse. [18],[19] PET has also been used to assess response early during the course of treatment. Early response assessment by PET is a good independent predictor of progression-free and disease-free survival in lymphoma patients. The ability of FDG PET to detect relapse earlier in nodes as well as additional sites not seen on CT lead to earlier administration of salvage therapy with a potential for better outcome.

 :: FDG PET in Malignant Melanoma Top

Malignant melanomas can metastasize to any part of the body and hence the best imaging option would be the one which would image the entire body. Whole body FDG PET is the most suitable imaging modality for assessing melanoma. In Stage I disease where the survival rates are higher than 85-90%, PET may not influence management or survival. [20] Likewise in advanced Stage IV disease with a poor survival PET may not be able to change management or influence survival. For Stage II disease, sentinel node biopsy because of its ability to detect micrometastasis has been proven to be superior to PET. [21] It is in Stage III disease with regional nodal metastases that PET has maximum impact as it can unmask distant metastatic sites and thus influence management regarding surgery with or without adjuvant treatment. It has a similar impact on potentially limited or surgically resectable Stage IV disease, where it can detect occult metastatic sites and prevent futile surgical procedures.

 :: FDG PET in Breast Cancer Top

The main role of FDG PET is breast cancer is detection of metastatic disease. PET scan can be useful in patients with non-palpable breast lesions, dense breasts, equivocal mammography results and after mammoplasty. The sensitivity and specificity of PET to detect the primary lesion range from 80-100%. [22] The most important advantage of PET at initial staging is the detection of unsuspected distant metastases in one single study. It can also detect internal mammary nodal involvement which is not routinely sampled at surgery. Though PET has shown reasonable sensitivity and specificity for detection of axillary nodal metastasis, it is limited in its ability to detect micrometastasis. Also, it cannot demonstrate the number of involved nodes which is a very important prognostic factor.

The ability of PET to accurately stage loco-regional recurrence in breast cancer is very important because though most recurrences are treated with systemic treatment, isolated loco-regional recurrences or solitary metastatic sites can also be treated with surgery and radiation therapy. [23]

Patients who undergo induction chemotherapy before surgery for locally advanced breast cancer benefit from PET scan as it allows differentiation of responders from non-responders early in the course of treatment. FDG PET has also been proven to be superior to bone scintigraphy (radionuclide bone scan) in detecting osteolytic skeletal metastases in breast cancer patients. [24]

 :: FDG PET in Colorectal Cancer Top

The important role of PET in staging colorectal cancer is in assessing regional nodal involvement and distant metastases. At the time of the initial surgery of Colorectal Cancer (CRC) hepatic metastases are present in up to 10-25% cases. PET has been found to be superior to CT scan in the identification of hepatic metastases with sensitivity of 88% and specificity of 100% for PET versus 38% and 97% respectively for CT. [25]

About 25% of operated CRC fail loco-regionally and about 20% show isolated recurrence that is amenable for surgical excision. PET is accurate in detecting pelvic recurrences and differentiating them from post-treatment fibrosis which shows similar features on CT. Intrahepatic metastasis can be treated with curative surgical resection whereas presence of extrahepatic disease precludes surgery. PET has a greater sensitivity and specificity for detection of both intra and extrahepatic disease than conventional imaging and can lead to management change in about 18-43% cases when recurrent or metastatic CRC is suspected. [26],[27] After treatment of hepatic metastasis with procedures such as radio frequency ablation and transarterial chemoembolisation, PET is often used to differentiate between post-treatment changes and residual/recurrent disease. Recurrent disease in the ablated region or elsewhere is picked up early by PET as compared to CT.

 :: Somatostatin Receptor PET and Scintigraphy for Neuroendocrine Tumors Top

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms that arise from the neural crest. These tumors have an ability to overexpress somatostatin (SST) receptors. Scintigraphy with radiolabeled SST analogues with 123 I, 111 In and 99m Tc have been used so far to diagnose these tumors. Somatostatin receptor scintigraphy (SRS) though is useful for whole body imaging, has certain limitations in organs with high physiological uptake like the liver and for detection of small lesions due to the detection limitations for Single photon emission computed tomography (SPECT ). Though FDG PET has a much higher spatial resolution and is widely used for oncology it is not primarily recommended for NET due to its poor sensitivity to detect tumors with low metabolic activity and slow growth. [28] Morphologic imaging modalities like contrast-enhanced CT scan provide excellent spatial resolution of images and can detect very small tumors of neuroendocrine origin, but they lack the specificity to diagnose malignant involvement as they rely on size and contrast enhancement criteria.

PET technology using 68Ga-labeled 1, 4, 7, 10 - tetraazacyclododecane-N, N9, N99, N999-tetraacetic acid-D-Phe1-Tyr3- octreotide (68Ga-DOTA-TOC) has shown promising results in various studies.

It has been shown to have a much higher diagnostic accuracy for detection and staging of NET as compared to SRS and CT scanning [Figure 3]. With easier and more widespread availability of the radioisotope, PET with 68 Ga-DOTA-TOC studies will certainly be the cornerstone of neuroendocrine tumor imaging in the near future.

 :: Detection of Bone Metastasis using F-18 Fluoride PET-CT Top

Conventional bone scanning is still the most common procedure for assessing bone metastasis in cancers with high risk of skeletal involvement like breast, lung and prostate cancers etc. However, it lacks specificity in accurately differentiating benign processes from malignant involvement.

F-18 fluoride is a PET tracer which can be used for bone imaging and has the same mechanism of uptake as other bone scintigraphic agents used in nuclear imaging. There are now a few studies in the literature stating the higher sensitivity of F-18 fluoride PET-CT over bone scanning with Tc-99m-methylene diphosphonate (MDP) [Figure 4]. Also, the specificity increases due to the CT component of the PET-CT which gives precise anatomic correlation and identifies nonspecific benign processes. [29]

 :: Conclusion Top

Imaging modalities are evolving at a staggering pace to provide improved evaluation of cancer. Our understanding of imaging criteria and experience in image interpretation are also improving. In addition to the traditional roles of imaging in cancer (i.e., localization and staging), extensive research is being done on functional and metabolic imaging with PET imaging to predict cancer aggressiveness and monitoring therapeutic response. Future developments in onco-imaging include more precise patient stratification for different management options and novel methods for guidance and assessment of newer cancer therapies. Judgments about which particular therapy or combination of therapies is optimal for a given patient often hinges on the results of imaging examinations. As the incidence of cancer rises due to rising life expectancy, the role of FDG PET will continue to expand with more indications getting approved and newer tumor-specific radio-isotopes being developed.

 :: References Top

1.Warburg O, Wind F, Negelein E. The metabolism of tumors. J Gen Physiol 1927;8:519-30.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]  
2.Wahl RL. Targeting glucose transporters for tumour imaging: "Sweet" idea, "sour" result. J Nucl Med 1996;37:1038-41.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]  
3.Alberico RA, Husain SH, Sirotkin I. Imaging in head and neck oncology. Surg Oncol Clin N Am 2004;13:13-35.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]  
4.Schwartz DL, Rajendran J, Yueh B, Coltrera M, Anzai Y, Krohn K, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg 2003;129:1173-8.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]  
5.Schoder H, Carlson DL, Kraus DH, Stambuk HE, Gφnen M, Erdi YE, et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47:755-62.  Back to cited text no. 5      
6.Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004;34:180-97.  Back to cited text no. 6      
7.Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005;115:645-50.  Back to cited text no. 7  [PUBMED]  [FULLTEXT]  
8.McDougall IR, Davidson J, Segall GM. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 2001;22:485-92.  Back to cited text no. 8  [PUBMED]  [FULLTEXT]  
9.Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 2001;28:1671-6.  Back to cited text no. 9  [PUBMED]  [FULLTEXT]  
10.Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005;79:375-382.  Back to cited text no. 10  [PUBMED]  [FULLTEXT]  
11.Verboom P, Van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: The PLUS study. Eur J Nucl Med Mol Imaging 2003;30:1444-9.  Back to cited text no. 11  [PUBMED]  [FULLTEXT]  
12.Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1943-51.  Back to cited text no. 12  [PUBMED]  [FULLTEXT]  
13.MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-92.  Back to cited text no. 13      
14.Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.  Back to cited text no. 14  [PUBMED]  [FULLTEXT]  
15.Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkins disease and Non Hodgkins lymphoma. Eur J Nucl Med Mol Imaging 2003;30:S82-8.  Back to cited text no. 15  [PUBMED]  [FULLTEXT]  
16.Fuster DA, Chiang SA, Andreadis C, Guan L, Zhuang H, Shuster S, et al. Can [18F] flurodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun 2006;27:11-5.  Back to cited text no. 16      
17.Filmont J, Ko Yang F, Yap C. Prediction of malignancy grade using 18 FDG - PET in non Hodgkins lymphoma patients: An urban legend ? J Nucl Med 2002;43:79.  Back to cited text no. 17      
18.Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, et al. FDG PET in the follow up management of patients with newly diagnosed Hodgkins and Non Hodgkins Lymphoma after first line chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:307-15.  Back to cited text no. 18  [PUBMED]  [FULLTEXT]  
19.Guay C, Lepine M, Verreault J, Bernard F. Prognostic value of PET using 18F-FDG in Hodgkins Disease for post treatment evaluation. J Nucl Med 2003;44:1225-31.   Back to cited text no. 19      
20.Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.  Back to cited text no. 20  [PUBMED]  [FULLTEXT]  
21.Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial: Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63; discussion463-5.  Back to cited text no. 21  [PUBMED]  [FULLTEXT]  
22.Wahl RL, Cody R, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-70.  Back to cited text no. 22      
23.Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 2000;18:2817-27.  Back to cited text no. 23  [PUBMED]  [FULLTEXT]  
24.Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000;88:2927-33.  Back to cited text no. 24  [PUBMED]  [FULLTEXT]  
25.Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings. Radiology 1998;206:755-60.  Back to cited text no. 25  [PUBMED]  [FULLTEXT]  
26.Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol1997;4:613-20.  Back to cited text no. 26  [PUBMED]    
27.Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrentcolorectal cancer: Comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22.  Back to cited text no. 27  [PUBMED]  [FULLTEXT]  
28.Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose PET for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998;25:79-83.  Back to cited text no. 28      
29.Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287-97.  Back to cited text no. 29  [PUBMED]  [FULLTEXT]  


  [Figure 1], [Figure 2], [Figure 3], [Figure 4]

This article has been cited by
1 Planning of nuclear medicine in Turkey: Current status and future perspectives
Goksel, F. and Peksoy, I. and Koc, O. and Gultekin, M. and Ozgul, N. and Sencan, I.
Asian Pacific Journal of Cancer Prevention. 2012; 13(5): 1989-1994
2 Planning of Nuclear Medicine in Turkey: Current Status and Future Perspectives
Fatih Goksel,Irfan Peksoy,Orhan Koc,Murat Gultekin,Nejat Ozgul,Irfan Sencan
Asian Pacific Journal of Cancer Prevention. 2012; 13(5): 1989
[Pubmed] | [DOI]


Print this article  Email this article
Previous article Next article
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow